Connect with us

BioPharma

Exxe Group Inc (OTCMKTS: AXXA) Powerful Move as Fintech Operator Reports Record Revenues & Advances in the Metaverse Ecosystem

Published

on

Exxe Group Inc (OTCMKTS: AXXA) continues to move steadily higher with power in recent days since days emerging as a top traded stock in small caps trading $6 million in dollar volume on Monday alone. Currently under heavy accumulation AXXA is quickly turning into an investor favorite and is currently among the most actively searched and talked about stocks in small caps. AXXA is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over February highs of $0.179 and its blue skies ahead for AXXA. 

There is a lot to get excited about AXXA; an early adopter of the Metaverse projected to reach $800 billion in 2024 according to a recent analysis by Bloomberg, IDC, PWC, Statista, and Two Circles. AXXA is already doing big numbers recently reporting it generated record quarterly results for both revenue and net income for the 3rd quarter. Revenue for 1Q22 was $13,279,551 as compared with $8,154,139 for the same period a year ago, and $11,022,713 for 1Q22 which ended just ninety days earlier. As noted in the table above, revenue increased by 62.9% year-over-year and 20.5% sequentially. Net income was $2,894,289 versus $1,249,894 last year and $1,831,875 in 1Q22. The Company’s real estate portfolio includes a collection of commercial real estate assets including hotels, mortgages, rental properties, and undeveloped land located in Germany, Switzerland, Eastern Europe, Canada and the US. 

Exxe Group Inc (OTCMKTS: AXXA) is a diversified fintech corporation focusing on acquisitions in the following sectors: real estate, sustainable technology, media, agribusiness, and financial services. Exxe Group is an acquisition-driven company. The Company strategy is to acquire controlling equity interests in undervalued companies and undertake an active role in improving their performance – accelerating their growth by providing both access to capital and management expertise. Since 2018 Exxe Group has successfully executed 28 acquisitions across several industries. 

The Company operates 4 subsidiaries in Real Estate, FinTech, Digital & Diversified Technologies, and Agribusiness. AXXA diversified asset base includes majority controlling interests in multiple entities across a wide range of industries and countries, as well as minority interests in selected startups. The Company’s real estate portfolio includes a collection of commercial real estate assets including hotels, mortgages, rental properties, and undeveloped land located in Germany, Switzerland, Eastern Europe, Canada and the US. 

Exxe has enjoyed substantial revenue and net income growth in the current FY22 fiscal year, ending in March 2022.  The Company generated record quarterly results for both revenue and net income for the 3rd quarter. Revenue for 1Q22 was $13,279,551 as compared with $8,154,139 for the same period a year ago, and $11,022,713 for 1Q22 which ended just ninety days earlier. As noted in the table above, revenue increased by 62.9% year-over-year and 20.5% sequentially. Net income was $2,894,289 versus $1,249,894 last year and $1,831,875 in 1Q22. The substantial year-over-year and sequential changes in net income were 131.5% and 58%, respectively. The Compnay is targeting record revenue and net income for the current year of $49M-$53M and a net margin of 15-20%. Based on current and projected trends of key business lines, AXXA continues to target outsized growth from current business and prospective acquisitions.  

AXXA is an early adopter of the Metaverse projected to reach $800 billion in 2024 according to a recent analysis by Bloomberg, IDC, PWC, Statista, and Two Circles. The Metaverse represents the convergence of the physical and digital worlds and the next stage in the evolution of the internet, e-commerce, social networks, and digital communities. This market presents a unique opportunity for a rare set of early adopters that have the capabilities to capitalize on these new revenue streams. Management believes AXXA is well-positioned through leverage of Exxe’s success in physical M&A and business management, along with its digital strategy which already encompasses core tenets of the Metaverse. Thus, Exxe’s initiative sets the stage for broad participation in the growth of the Metaverse ecosystem. 

To find out the inside scoop on AXXA Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

AXXA

As an early adopter, Exxe stands to potentially generate major returns on investment and revenue growth. Initial steps have been established during 2021, leveraging our digital communities and including the digital asset purchase of land inside of popular and emerging spaces in the Metaverse. According to Bloomberg, content, and offerings that successfully pivot towards the digital world can capture greater user engagement both in the Metaverse and in the physical world, thereby accelerating revenue and fostering brand and consumer loyalty. 

Other prospective steps include the establishment of AXXA-centric, diversified offerings throughout the ecosystem. For example, Daskonzept’s in-demand online design capabilities, coupled with the 1Myle cryptocurrency provide Exxe with major leverage and an early mover advantage over companies who have exposure to the Metaverse or are contemplating such moves. Exxe blends experience in generating ROI on physical real estate, revenue from online design, and other critical concepts. Importantly, since transactions must be executed in digital currencies, Exxe has a rare advantage over nearly all firms in the space since 1Myle is an active crypto swaps exchange and services provider. As a result, management plans to announce its expanding presence and offerings in the Metaverse, along with revenue and ROI growth throughout 2022. 

On December 9 AXXA announced its plans to transform the way real estate and business services industries conduct business while concurrently serving as early adopters and providers of digital assets, products, and services as part of the AXXA Metaverse Initiative. At the strategy’s core, the Company is already simultaneously expanding its reach in the two key segments: physical real estate and digital real estate assets. In this fashion, Exxe serves as a two-way digital and physical conduit and can integrate its successful approaches in physical business M&A with its digitization strategy, thus utilizing these methodologies to rapidly take advantage of lucrative opportunities in the Metaverse. 

In recent months, management has alluded to an opportunity to acquire, in stages, commercial and residential assets whose values should approach an estimated $100M. The first stage is set to close in early 2022 of which the first ten million will be added in the current quarter and it is anticipated that with each closed stage, $25M in assets should be added to the Company’s real estate portfolio, per quarter. The portfolio includes approximately 250 residential units along with commercial property and land. The property is mostly dispersed throughout Germany’s largest cities along with other Western European nations. Management anticipates that traditional revenue will be generated from these commercial and residential properties along with other recurring revenue via the introduction and leverage of its digitization and services integration strategy to current and future tenants in these properties. The path to closing on $100M in properties will be detailed in future releases on a staged basis, beginning in early 2022. 

For More on AXXA Subscribe Right Now!

AXXA continues to move steadily higher with power in recent days since days emerging as a top traded stock in small caps trading $6 million in dollar volume on Monday alone. Currently under heavy accumulation AXXA is quickly turning into an investor favorite and is currently among the most actively searched and talked about stocks in small caps. AXXA is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over February highs of $0.179 and its blue skies ahead for AXXA. There is a lot to get excited about AXXA; an early adopter of the Metaverse projected to reach $800 billion in 2024 according to a recent analysis by Bloomberg, IDC, PWC, Statista, and Two Circles. AXXA is already doing big numbers recently reporting it generated record quarterly results for both revenue and net income for the 3rd quarter. Revenue for 1Q22 was $13,279,551 as compared with $8,154,139 for the same period a year ago, and $11,022,713 for 1Q22 which ended just ninety days earlier. As noted in the table above, revenue increased by 62.9% year-over-year and 20.5% sequentially. Net income was $2,894,289 versus $1,249,894 last year and $1,831,875 in 1Q22. The Company’s real estate portfolio includes a collection of commercial real estate assets including hotels, mortgages, rental properties, and undeveloped land located in Germany, Switzerland, Eastern Europe, Canada and the US. We will be updating on AXXA when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with AXXA.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in AXXA either long or short and we have not been compensated for this article

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

BioPharma

Vaccitech (NASDAQ: VACC) Gains Unprecedented Support—What’s Behind It?

Published

on

On September 25, 2023, Vaccitech (NASDAQ: VACC) experienced a jaw-dropping 90% surge in its stock price in just one day of trading. Now, this kind of jump usually happens when a company drops a major announcement or puts out a significant SEC filing. But, surprise, surprise—there was nothing of that sort this time .So naturally we did some digging, explored further online and guess what? Turns out retail traders were also not on a main reason for this rollercoaster ride. Curious to uncover what’s really behind this financial rollercoaster? Before we go any further, let’s get to know Vaccitech a bit better. There’s some pretty important aspects on the company you might like.

 

Background:

Vaccitech operates as a clinical-stage biopharmaceutical company, dedicated to discovering and developing innovative T cell immunotherapies. These therapies are crafted to leverage the immune system’s potency for treating conditions like chronic infectious diseases, cancer, and autoimmune disorders.

What sets Vaccitech apart is their distinctive, multi-platform approach, demonstrating the capacity to generate higher quantities of T cells compared to alternative technologies. This places Vaccitech in a unique position to cater to the needs of substantial, yet underserved patient populations. Their diverse clinical-stage pipeline includes potential treatments for severe diseases with limited available treatments, presenting significant public health risks.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Among their lead product candidates are VTP-300, an immunotherapeutic designed to contribute to a potential functional cure for chronic hepatitis B viral (HBV) infection. Additionally, VTP-200 is a non-invasive, early-stage investigational treatment targeting persistent, high-risk human papillomavirus (HPV). VTP-850 stands out as a novel T cell investigational therapy aimed at prostate cancer, while VTP-1000, a preclinical T cell therapeutic candidate, focuses on reinstating immune tolerance in celiac disease.

Vaccitech possesses well-established expertise in drug development and scientific knowledge within the immunization realm. Notably, they co-developed a COVID-19 vaccine in collaboration with the University of Oxford. As many of you know, their vaccine has been successfully approved and holds an exclusive license worldwide with AstraZeneca.

What happened:

The one and only thing that happened today was Alliance Global Partners adding coverage of Vaccitech with a favourable buy recommendation.What’s truly eye-catching are the projections made, suggesting some pretty significant upside. The average one-year price target for Vaccitech is $12.24. Forecasts within this period have a bit of a spectrum, reaching from a low estimate of $7.07 to a high of $15.75. With that said, from today’s closing price that’s nearly 400% gain.

What’s The Big Deal?:

Alliance Global Partners giving the green light to cover Vaccitech is like a thumbs-up from a respected expert. It’s like a top-tier food critic saying, “This restaurant is a must-try.”

Think of it as Vaccitech stepping into the spotlight. It’s like a talented musician getting featured on a famous music blog—suddenly, more people start paying attention.

When a big player like Alliance Global Partners says, “Hey, this stock is a good buy,” it’s like a friend recommending a must-watch movie. You’re more likely to check it out based on that suggestion.

This kind of recommendation can also affect the stock price. It’s similar to when a popular influencer talks about a cool product—lots of people want to try it.

In a nutshell, this coverage is like a stamp of approval, making Vaccitech catch the attention of more potential investors and possibly giving the stock a boost. But it’s important to mention that just because a well established financial firm gives a price target, does not mean it’s accurate. In fact, tons of these projections are made daily with many being totally off the mark. Always do your own due diligence.

We will update you on VACC when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by spencerbdavis1 from Pixabay

 

 

 

Continue Reading

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.